Printer Friendly

COMPANY INFORMATION
Labopharm Inc. 480 boul Armand-Frappier Laval, QC H7V 4B4 Tel: (450) 686-0207 Toll-free: (888) 687-5860 Fax: (450) 686-9141 Contact Name Mark A. D'Souza Industry Pharmaceuticals		Key Executives James R. Howard-Tripp, CEO Mark A. D'Souza, CFO Develops pharmaceutical products that incorporate the company's proprietary drug delivery technology Contramid®.
FP ADVISOR COVERAGE Labopharm Inc. • FP Corporate Analyzer • FP Directory of Directors • FP Corporate Surveys • FP Investor Reports • Ordering FP Products		TOP INDUSTRY PLAYERS Pharmaceuticals Company Name Revenue ($000s)  Biovail Corporation 936,111 Patheon Inc. 765,812 Cangene Corporation 238,751 Paladin Labs Inc. 109,693 Cardiome Pharma Corp. 54,672 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF SEPT. 8/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX/DDS NASDAQ/DDSS $0.97 $3.16 on Feb. 3/10 $0.75 on July 2/10 n.a. n.a. n.a. 0.68 Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap (000s) 66,126 n.a. $ -0.44 June 30/10 -34.01% -19.51% -27.79% $69,424
ANNUAL FINANCIALS Periods ended: 12m Dec. 31/09 12m Dec. 31/08 12m Dec. 31/07 $000s $000s $000s Operating revenue 24,572 22,014 18,998 Net income (26,110) (40,527) (36,575) Total assets 49,120 69,851 99,539 $ $ $ Earnings per share* (0.46) (0.71) (0.64) % % % Return on equity n.m. (127.55) (55.63)   * Common
TRAILING 12-MONTH VALUES Periods ended: June 30/10 June 30/09 $000s $000s Operating revenue 24,864 25,098 Net income (27,551) (33,543) $ $ Earnings per share (0.44) (0.60)

COMPANY NEWS

Results for 'Labopharm Inc.' from past 30 days: 1 hit. Labopharm net loss widens, shares slump National Post - Fri Aug 13 2010 - 82 words (Links are to articles.)